Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Mar 17, 2020 4:31pm

223 Views

Post# 30818794

RE:RE:SP could drop to mid 30s

The impact of the results will be blunted due to the pandemic, and poor faith in the markets right now....

Having said that, I posted this before, if you're looking to sell the news this isnt the best time. If you're in this for the long haul (i.e. through to partnerships or otherwise) it changes nothing. Mainly because the SP has nothing to do with valuation of the product/company.

I still see $1+ on results....how long that will be sustained, is anyones guess.

Stay safe, and practice good judgment in the market. These opportunistic times, but very risky as well. Economic tectonic are shifting overall.